SAB Biotherapeutics, Inc.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- $13.3M
- Total assets
- $172.8M
- Market cap
- $258.4M
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $49.0M
- Operating income
- -$49.0M
- Income tax
- $0
- Net income
- $13.3M
- EPS (basic)
- $0.22
- EPS (diluted)
- $-0.79
Balance sheet
- Total assets
- $172.8M
- Current assets
- $101.1M
- Total liabilities
- $21.3M
- Current liabilities
- $10.7M
- Shareholders’ equity
- $151.5M
Cash flow
- Operating cash flow
- -$44.8M
- Investing cash flow
- -$121.7M
- Financing cash flow
- $168.3M
- Net cash flow
- $1.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $258.4M
- EPS (diluted)
- $-0.79
- Shares outstanding
- 76.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 22, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $13.3M in FY2025.
- Trading 26% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review SAB Biotherapeutics, Inc..
Write a review
News about SAB Biotherapeutics, Inc.
News & sentiment via Polygon.io
